Targeted therapy against druggable genetic aberrations has shown a significantly positive response rate and longer survival in various cancers, including lung cancer. In lung adenocarcinoma (LADC), specific thyroxin kinase inhibitors against EGFR mutations and ALK fusions are used as a standard treatment regimen and show significant positive efficacy. On the other hand, targeted therapy against driver gene aberrations has not been adapted yet in small cell lung cancer (SCLC). This is because driver genes and druggable aberrations are rarely identified by next generation sequencing in SCLC. Recent advances in the understanding of molecular biology have revealed several candidate therapeutic targets. To date, poly [ADP-ribose] polymerase (PARP), enhancer of zeste homologue 2 (EZH2) or delta-like canonical Notch ligand 3 (DLL3) are considered to be druggable targets in SCLC. In addition, another candidate of personalized therapy for SCLC is immune blockade therapy of programmed death-1 (PD-1) and its ligand, PD-L1. PD-1/ PD-L1 blockade therapy is not a standard therapy for SCLC, so many clinical trials have been performed to investigate its efficacy. Herein, we review gene aberrations exploring the utility of targeted therapy and discuss blockade of immune checkpoints therapy in SCLC.
Introduction
Small cell lung cancer (SCLC) is an aggressive form of lung cancer with different clinical and pathological features from non-small cell lung cancer (NSCLC) and is characterized by rapid tumor development and metastasis (1) . Although SCLC has a poor prognosis, the standard chemotherapy for SCLC has not changed in the past three decades (2) . In 2002, a Phase III study (Japan Clinical Oncology Group [JCOG] 9511) demonstrated that the topoisomerase I inhibitor irinotecan plus cisplatin (IP) improved tumor response and survival time of patients with extensive-stage SCLC compared to etoposide plus cisplatin (3) . Although IP therapy is preferred as a first-line chemotherapy for patients with extensive-stage SCLC in Japan, this regimen did not show clinical benefit in the North American trial (4) . Therefore, a novel targeted therapy is extremely required to improve the treatment efficacy for SCLC. Recently, several large-scale genomic examinations using next generation sequencing have been performed and have revealed the genomic landscape of SCLC (5, 6) . In SCLC, mutations in TP53 and RB1 and amplifications of MYC family members, SOX2, and SRSF1, have been identified (7) . However, because druggable gene aberrations are rarely identified, a standard targeted therapy has not been developed in the clinical setting.
A recent study reported that rovalpituzumab tesirine (Rova-T), a delta-like canonical Notch ligand 3 (DLL3)-targeted antibody-drug conjugate (ADC), show substantial anti-tumor activity and durability in recurrent or refractory SCLC (8) . Furthermore, another study reported that poly [ADP-ribose] polymerase (PARP) and enhancer of zeste homologue 2 (EZH2) are potential novel therapeutic targets by specific inhibitors in SCLC (2) . The blockade of immune checkpoints in cancer immunotherapy have shown positive efficacy in both patients with squamous cell lung cancer and patients with nonsquamous NSCLC (9) (10) (11) (12) (13) (14) . Therefore, this immunotherapy is also expected to be a useful therapy for SCLC. To date, several clinical trials have started to evaluate blockade of the programmed death-1 (PD-1) and its ligand PD-L1. In this review, we introduce gene aberrations in SCLC and discuss candidate therapeutic options for SCLC.
Therapeutic advances in SCLC
Although SCLC is treated by chemotherapy in a similar way to NSCLC, there are not many treatment regimens available. First-line treatment for advanced SCLC is a platinum-based agent (either cisplatin or carboplatin) in combination with etoposide, as approved by the U.S. Food and Drug Administration (FDA), but this standard regimen has not changed in the past three decades (2) . Another regimen, such as a platinum-based agent with irinotecan, has not been confirmed as having better clinical benefits compared to platinumbased agent with etoposide (2). For second-line therapies in recurrent SCLC, topotecan is the only approved treatment by the FDA as a systemic chemotherapy among several agents, including docetaxel, paclitaxel, or gemcitabine (2) . However, almost all SCLC patients who initially benefited from those therapies eventually acquired resistance, resulting in a poor patient outcome. Therefore, targeted therapy against druggable targets and immunotherapy that could substitute chemotherapy are potential therapeutic options for SCLC.
Gene aberrations and targeted therapies for SCLC
Recently, many large-scale genome sequencing studies by The Cancer Genome Atlas (TCGA) and others have been performed in lung cancer, and these have revealed the genomic features of these tumors (5, 6, (15) (16) (17) (18) (19) . Among a huge number of genetic aberrations, gene aberrations, which are considered to have a pivotal role in cancer development, are called driver gene aberrations. The driver gene aberration leads to a state of oncogene addiction and, therefore, is considered to be a therapeutic target for specific inhibitors (20, 21) . To date, several driver genes have been identified in NSCLC, particularly in LADC (15, 16) . In LADC, gene mutations of EGFR, KRAS, BRAF and HER2, and gene rearrangements involving ALK, ROS1 and RET have been mutually exclusively detected (15, 17) , and their suppression results in the inhibition of LADC development and metastasis. In a clinical setting, targeted therapies using tyrosine kinase inhibitors (TKIs) against LADC tumors harboring EGFR mutations, ALK fusions and ROS1 fusions have already become a standard treatment and showed remarkable therapeutic effectiveness (22) (23) (24) (25) . Therefore, to find a druggable target from a huge number of identified genetic aberrations, several large-scale genome sequencing studies have been performed in SCLC (Table 1) .
Sequencing analysis has revealed that gene aberrations of TP53 and RB1 are most recurrently identified in SCLC (5, 6) . The conditional deletion of TP53 and RB1 in lung epithelial cells leads to the development of SCLC in mice, so it has been confirmed that the inactivation of these two major tumor suppressor genes may drive SCLC development (26) . However, gene aberrations of TP53 and RB1 have several limitations to becoming useful druggable targets. In TP53, while several hotspots mutations such as R175, G245, R248, R249, R273 and R282 have been identified, most of the mutated positions varied in different types of tumor. These various TP53 mutations are divided into two different functions, such as loss of function or gain of function mutations, that could not be evaluated by immunohistochemical (IHC) staining for p53 ( Fig. 1 ) (27) . These results suggested that different TP53 mutations result in different p53 functions. This fact has led to the necessity of various treatment approaches for mutant p53, including proteasome degradation, conversion to wild-type p53, autophagy-mediated degradation, interaction to other proteins, or inhibition of downstream signaling pathways (28) . A recent clinical trial reported that patients with SCLC treated by p53-modified adenovirus-transduced dendritic cell vaccine showed positive efficacy in SCLC patients (NCT00776295) (29) . Further clinical trials using this vaccine have been completed (NCT00049218), and other clinical trials on targeted TP53 mutations using AZD1775 are currently underway.
Amplifications of MYC-family genes, including MYCL1, MYCN and MYC, have also been recurrently identified in SCLC (5, 6, 30) . These focal amplifications are mutually exclusive and results in high MYC protein expression. Cell-based investigations have revealed that MYC proteins in SCLC are potential therapeutic targets by direct or indirect inhibition (31, 32) . Other candidate targetable aberrations in SCLC are gene mutations in CREBBP/CBP and EP300, histone acetylation enzymes, PTEN, and amplifications of SOXfamily genes, including SOX2 (33) (34) (35) . Although the oncogenic PI3K/AKT/mTOR pathway is activated in SCLC (18), the targeted therapy for this pathway has not been developed yet. In addition, similar to other cancers, because activating mutations in kinase genes have been rarely identified in SCLC, no kinase inhibitors have become a standard treatment for SCLC in the clinical setting. Recent analysis of somatic copy number alterations has revealed that amplification of FGFR1, one of the tyrosine kinase genes, is recurrently identified in SCLC (6) . Amplification of FGFR1 often leads to FGFR1 overexpression, suggesting its potential as a therapeutic target (36) . To date, many TKIs for FGFR1 amplifications have been generated and efficacy and safety tests have been conducted in many clinical trials (36, 37) .
Novel candidate targeted therapies for SCLC
Unlike LADC, targeted therapy for SCLC has not yet been developed due to the lack of druggable targets in SCLC. Under this situation, several specific inhibitors, such as poly [ADP-ribose] polymerase (PARP) inhibitors, enhancer of zeste homologue 2 (EZH2) inhibitors or DLL3-targeted antibody-drug conjugate (ADC), are currently under clinical investigation (2) . PARP inhibitors, olaparib, veliparib, and talazoparib and target PARP enzyme, which is involved in DNA damage repair, are the first clinically approved drugs designed to use synthetic lethality (38) . EZH2 inhibitors, such as GSK-126, tazemetostat, and CPI-1205, and target EZH2, which is involved in chromatin remodeling, are also designed to exploit synthetic lethality (39) . Most recently, Rova-T, a DLL3-targeted antibody-drug conjugate (ADC), showed substantial anti-tumor activity and durability in recurrent or refractory SCLC (8, 40) . It has been reported that DLL3 is overexpressed in most SCLC tumors and Rova-T showed a higher efficacy in SCLC patients with high DLL3 expression in tumors than those with low DLL3 expression (8) . In our recent study, we have performed IHC staining for EZH2 and DLL3 in Japanese SCLC patients and observed that EZH2 and DLL3 were also abundantly expressed in Asian populations ( Fig. 1) (41) . We then confirmed that IHC staining for EZH2 and DLL3 could be a therapeutic biomarker in SCLC. To date, several clinical trials for extensive stage SCLC are ongoing and outcome is awaited.
Immune blockade therapy for SCLC
The immune checkpoint blockade of PD-1 and its ligand PD-L1 is expected to be an additional targeted therapy for SCLC. The blockade of interactions between PD-1 and PD-L1 overcomes immune resistance and has been shown to have durable positive efficacy in patients with NSCLC (9, (11) (12) (13) (14) . To date, anti-PD-1 drugs, nivolumab and pembrolizumab, and anti-PD-L1 drug, atezolizumab, have been approved for treatment-refractory unresectable NSCLC in the US and Japan (21) . Pembrolizumab has also been approved for treatment-naive patients with NSCLC with high PD-L1 expression based on immunohistochemistry and EGFR and ALK wild type (42) . These drugs are also expected to become a therapeutic regimen for SCLC. Though the data from clinical trials are preliminary, nivolumab (CheckMate 032) and pembrolizumab (KEYNOTE 028) have demonstrated positive efficacy and acceptable safety in patients with advanced SCLC (Table 2) . Further clinical trials are currently underway to evaluate the efficacy of anti-PD-1 or anti-PD-L1 drugs for SCLC. Among these trials, a clinical trial (KEYNOTE 158) has evaluated predictive biomarkers for pembrolizumab and is currently recruiting participants with various malignancies, including SCLC. While this immunotherapy shows significant positive efficacy, not all cases result in significant tumor shrinkage. Therefore, it is necessary to identify predictive biomarkers to find patients who receive the best clinical benefits from the PD-1/PD-L1 blockade. Positive IHC staining for PD-L1 in tumors appears to predict high efficacy of nivolumab in NSCLC. However, IHC staining for PD-L1 has not been well standardized and various anti-PD-L1 antibodies have been used in various assessment methods. To date, some candidate predictive biomarkers rather than IHC staining for PD-L1 have been reported, such as mutation burden or mismatchrepair deficiency, to aid the further expansion of this immunotherapy as a personalized therapy (43) .
CD274/PD-L1 expression in SCLC
We have previously reported that arm-level or focal amplifications of the 9p24.1 region were found in a small subset of SCLC cases (30) . This region included CD274/PD-L1, which is a target of immune blockade therapy. By examining somatic copy number alterations in primary SCLC specimens, we observed 9p24 copy number gains (where CD274 resides) and focal high-level amplification of CD274 (44). When we compared PD-L1 expressions with DNA copy numbers or mRNA expressions in the same tumor, positive PD-L1 staining cases were tumors with highly focally amplified CD274, not tumors with arm-level copy number gain (Fig. 2) . CD274 amplification was caused by genomic rearrangements not affecting the open reading frame, leading to massively increased CD274 transcripts and positive IHC staining for PD-L1. Therefore, Compared with other studies that evaluate PD-L1 expression by different anti-PD-L1 antibodies (E1L3N), fewer tumors with positive staining for PD-L1 were detected in our cohort. This is due to the high specificity of the anti-PD-L1 antibody that was used in our study. Therefore, this antibody may be suitable to find patients with strictly elevated PD-L1 expression by gene amplification. Although it is still controversial whether PD-L1 expression is associated with the response of the anti-PD-1 antibody, tumors with high PD-L1 expression may be particularly susceptible to immune checkpoint blockade therapy. Unfortunately, we were unable to evaluate the therapeutic efficacy of the anti-PD-1/PD-L1 blockade for patients with high PD-L1 expressions. Our data demonstrated that SCLC patients with a higher copy number of CD274 have poorer overall survival than those with a lower copy number (P = 0.0026 by Kaplan-Meier analysis) (Fig. 3) . The limitation of this analysis is that it includes many early-censored patients. Although this imbalance in the population may affect the reliability of the results, our survival analysis suggests that SCLC patients with CD274 amplification require additional treatment to improve survival.
Conclusion
To date, molecular targeted therapy and immunotherapy for LADC have significantly progressed, but not so for SCLC. The need of these therapies for SCLC is significantly increasing and many clinical trials are currently underway to evaluate the clinical efficacy and safety of these therapies. Rova-T and immune blockade therapy are expected to become an effective therapy for SCLC.
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